Compare Stocks

→ Exposed: How Big Banks Plan to Chain Your Wealth with Digital Dollars (From GoldenCrest Metals) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACST Acasti Pharma	$2.88 +1.1%	$3.32	$1.72 ▼ $3.84	$26.79M	1.49	28,834 shs	4,477 shs
ADMS Adamas Pharmaceuticals	$8.22	$8.17	$4.02 ▼ $9.15	$376.37M	2.82	692,487 shs	N/A
AVEO AVEO Pharmaceuticals	$15.00	$14.97	$3.06 ▼ $15.00	$521.45M	1	601,442 shs	247,800 shs
SAVA Cassava Sciences	$20.55 +0.2%	$21.57	$12.32 ▼ $32.10	$886.54M	-0.45	955,046 shs	498,564 shs
ZSAN Zosano Pharma	$0.00	$3.90	$0.46 ▼ $37.45	$1K	3.3	425,375 shs	5,685 shs

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACST Acasti Pharma	+1.05%	-14.54%	-15.29%	+19.50%	+0.13%
ADMS Adamas Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
AVEO AVEO Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
SAVA Cassava Sciences	+0.24%	-2.28%	+3.74%	-17.67%	+26.02%
ZSAN Zosano Pharma	0.00%	0.00%	0.00%	0.00%	0.00%

Exposed: How Big Banks Plan to Chain Your Wealth with Digital Dollars (Ad)

Big Banks have declared war on your wallet. But it's not too late to fight back. Discover how to protect your assets from their latest maneuver.

Learn More Now

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACST Acasti Pharma	2.5252 of 5 stars	3.5	5.0	0.0	0.0	0.6	0.8	1.3
ADMS Adamas Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
AVEO AVEO Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SAVA Cassava Sciences	3.4894 of 5 stars	3.5	1.0	0.0	4.7	1.7	0.8	0.6
ZSAN Zosano Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACST Acasti Pharma	3.00	Buy	$6.00	108.33% Upside
ADMS Adamas Pharmaceuticals	N/A	N/A	N/A	N/A
AVEO AVEO Pharmaceuticals	N/A	N/A	N/A	N/A
SAVA Cassava Sciences	3.00	Buy	$124.00	503.41% Upside
ZSAN Zosano Pharma	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest AVEO, SAVA, ACST, ADMS, and ZSAN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
3/5/2024	SAVA Cassava Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$124.00
2/7/2024	ACST Acasti Pharma	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$6.00

(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACST Acasti Pharma	N/A	N/A	N/A	N/A	$9.14 per share	N/A
ADMS Adamas Pharmaceuticals	$74.46M	5.05	N/A	N/A	($0.47) per share	-17.49
AVEO AVEO Pharmaceuticals	$42.29M	12.33	N/A	N/A	$1.33 per share	11.28
SAVA Cassava Sciences	N/A	N/A	N/A	N/A	$3.26 per share	N/A
ZSAN Zosano Pharma	$790K	0.00	N/A	N/A	$9.74 per share	0.00

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACST Acasti Pharma	-$42.43M	-$5.08	N/A	N/A	N/A	N/A	-13.18%	-11.32%	6/28/2024 (Estimated)
ADMS Adamas Pharmaceuticals	-$57.40M	-$1.70	N/A	N/A	N/A	-71.11%	N/A	-42.96%	N/A
AVEO AVEO Pharmaceuticals	-$53.34M	-$0.84	N/A	28.85	N/A	-30.79%	-81.66%	-28.83%	N/A
SAVA Cassava Sciences	-$97.22M	-$2.32	N/A	12.31	N/A	N/A	-57.53%	-52.58%	5/6/2024 (Estimated)
ZSAN Zosano Pharma	-$29.92M	-$14.50	N/A	∞	N/A	-8,375.11%	-177.06%	-119.14%	N/A

Latest AVEO, SAVA, ACST, ADMS, and ZSAN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
2/28/2024	Q4 2023	SAVA Cassava Sciences	-$0.40	-$0.50	-$0.10	-$0.50	N/A	N/A
2/12/2024	12/31/2023	ACST Acasti Pharma	-$0.23	-$0.21	+$0.02	-$0.21	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACST Acasti Pharma	N/A	N/A	N/A	N/A	N/A
ADMS Adamas Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
AVEO AVEO Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SAVA Cassava Sciences	N/A	N/A	N/A	N/A	N/A
ZSAN Zosano Pharma	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACST Acasti Pharma	N/A	15.19	15.19
ADMS Adamas Pharmaceuticals	21.25	4.53	4.17
AVEO AVEO Pharmaceuticals	0.94	2.37	2.35
SAVA Cassava Sciences	N/A	9.13	9.13
ZSAN Zosano Pharma	N/A	1.61	1.61

Ownership

Institutional Ownership

Company	Institutional Ownership
ACST Acasti Pharma	6.08%
ADMS Adamas Pharmaceuticals	69.97%
AVEO AVEO Pharmaceuticals	49.95%
SAVA Cassava Sciences	38.05%
ZSAN Zosano Pharma	N/A

Insider Ownership

Company	Insider Ownership
ACST Acasti Pharma	13.51%
ADMS Adamas Pharmaceuticals	18.90%
AVEO AVEO Pharmaceuticals	3.29%
SAVA Cassava Sciences	12.20%
ZSAN Zosano Pharma	2.40%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ACST Acasti Pharma	32	9.40 million	8.13 million	Not Optionable
ADMS Adamas Pharmaceuticals	138	45.79 million	37.13 million	Optionable
AVEO AVEO Pharmaceuticals	114	34.76 million	33.62 million	Optionable
SAVA Cassava Sciences	29	43.25 million	37.97 million	Optionable
ZSAN Zosano Pharma	40	4.90 million	4.78 million	Not Optionable

AVEO, SAVA, ACST, ADMS, and ZSAN Headlines

Source	Headline
	HOOK HOOKIPA Pharma Inc. seekingalpha.com - April 12 at 10:11 PM
	Nachrichten - Weitere Nachrichten wallstreet-online.de - January 9 at 2:39 PM
	LISTEN: Supreme Court hears arguments on legality of Purdue Pharma bankruptcy plan pbs.org - December 6 at 7:44 AM
	Der Börsen-Tag: Diese US-Aktie stürzte nachbörslich ab n-tv.de - August 22 at 3:36 PM
	East Bay Business News bizjournals.com - May 18 at 9:49 PM
	Mankind Pharma IPO opens on April 25, listing scheduled for May 9 moneycontrol.com - April 27 at 4:20 PM
	Astellas Pharma forbes.com - April 6 at 12:00 PM
	Giiant Pharma Receives Financial Support From the US Crohn’s and Colitis Foundation finance.yahoo.com - February 5 at 12:11 PM
	FTC asks court to hold 'pharma bro' Martin Shkreli in contempt for failing to abide by orders washingtonexaminer.com - January 23 at 3:25 PM
	Zosano Pharma Corporation (ZSANQ) ca.finance.yahoo.com - November 5 at 6:33 PM
	Now bankrupt, Zosano sells off its drug delivery tech that once enticed Novo Nordisk, Eli Lilly endpts.com - October 13 at 11:22 AM
	Bankrupt Zosano Sells Its Drug Delivery Tech That Once Partnered With Pharma Giants msn.com - October 12 at 2:32 PM
	Bankrupt Zosano Pharma Says Unsecured Creditors Will Recoup 28% of Claims marketwatch.com - August 28 at 7:45 PM
	East Bay migraine patch developer Zosano closes sale in bankruptcy court for $1 million bizjournals.com - August 27 at 4:10 PM
	Zosano Pharma Corp (ZSANQ) investing.com - August 25 at 12:28 AM
	East Bay company promised drug-coated microneedle patches. Now it could be sold in bankruptcy court for just $1M bizjournals.com - July 26 at 8:27 PM
	A Fremont company promised drug-coated microneedle patches. Now it could be sold in bankruptcy court for just $1M. bizjournals.com - July 26 at 8:27 PM
	Zosano Pharma Corporation [ZSAN] stock Initiated by Maxim Group analyst, price target now $8 dbtnews.com - June 3 at 11:27 AM
	Zosano Pharma Shares Slide to New Depths After Chapter 11 Filing >ZSAN marketwatch.com - June 2 at 3:26 PM
	Why Zosano Pharma Shares Are Getting Hammered Today msn.com - June 2 at 3:26 PM
	Zosano Pharma files for Chapter 11 bankruptcy protection; shares plummet 46% seekingalpha.com - June 2 at 10:26 AM
	Cash-Strapped Zosano Pharma Files for Chapter 11 Bankruptcy >ZSAN marketwatch.com - June 2 at 10:26 AM
	East Bay migraine patch developer files for bankruptcy bizjournals.com - June 2 at 10:26 AM
	Zosano Pharma Files Voluntary Petition for Relief Under Chapter 11 finance.yahoo.com - June 2 at 10:26 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Acasti Pharma

NASDAQ:ACST

Acasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Laval, Canada.

Adamas Pharmaceuticals

NASDAQ:ADMS

Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.

AVEO Pharmaceuticals

NASDAQ:AVEO

AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.

Cassava Sciences

NASDAQ:SAVA

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

Zosano Pharma

NASDAQ:ZSAN

Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system. Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the acute treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial